This section is part 6 of the PHE pneumococcal guideline summary.
Contents included in this summary
Anyone can report a suspected adverse reaction to the Medical and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme (http://yellowcard.mhra.gov.uk/).
The safety of the vaccine was assessed in controlled clinical studies and the safety profile of Prevenar13® was similar to Prevenar®. For Prevenar13®, the most commonly reported adverse reactions in children 6 weeks to 5 years of age were vaccination-site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep. Reports of all adverse reactions can be found in the summary of product characteristics for Prevenar 13® available at https://www.medicines.org.uk.
Mild soreness and induration at the site of injection lasting one to three days and, less commonly, a low grade fever may occur. More severe systemic reactions are infrequent. In general, local and systemic reactions are more common in people with higher concentrations of antibodies to pneumococcal polysaccharides.
full guideline available from…
Public Health England. Immunisation against infectious disease (Green Book). London: Public Health England, 2018.
Contains public sector information licensed under the Open Government Licence v3.0.
First included: May 2019.